Dumitru Lupuleasa

Dumitru Lupuleasa

Auto-generated profile, based on publicly available information

Dumitru Lupuleasa

Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy,“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Letters in Drug Design & Discovery
Verified
Journal Article
Closed access
PDF file
RBRica Boscencu
Rica Boscencu
Gina MandaGina Manda
Gina Manda
GVGeorgiana Vasiliu
Georgiana Vasiliu
RSRadu Socoteanu
Radu Socoteanu
DLDumitru Lupuleasa
Dumitru Lupuleasa
LOLaura Olariu
Laura Olariu
Background: Tetrapyrrolic compounds, such as porphyrins and metalloporphyrins, are highly interesting for pharmaceutical chemistry designs considering their good biocompatibility and therapeutic potential. Objective: The aim of the present work was a preliminary in vitro evaluation of some unsymmetrical porphyrins and the corresponding symmetrical structures, as potential candidates for the photodynamic therapy of malignant tumors. Method: The biocompatibility compounds were assessed in terms of their in vitro effect on the viability and proliferation of breast human carcinoma MCF-7 cells and human normal peripheral blood mononuclear cells (PBMCs). Results: Results indicated that unsymmetric and symmetric porphyrins were non-toxic against tumor MCF-7 cells and PBMCs in the concentration range 0.2–2µM, making them valuable candidates for further development as photosensitizers for PDT in tumors. Moreover, unsymmetric compounds tended to restore the response of normal and tumor cells affected by the vehicle (dimethyl sulfoxide) used for the initial solubilization of porphyrins, while the symmetric compounds were less active in this respect. Conclusion: Unsymmetric A3B type porphyrins prove enhanced capacity as potential theranostic agent in interaction with human carcinoma MCF-7 cells, despite reduced differences with the corresponding symmetrical form.